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The prionoses are fatal neurodegenerative diseases caused by a pathogenic protein, PrP scrapie,
that derives from misfolding of a normal form, PrPc. These diseases progress through stages. A
new study by Mallucci et al. in this issue of Neuron shows that prion disease may be reversed in
mice by selective removal of the gene in neurons after early physiological, cognitive, and pathological
features have developed.In this issue of Neuron, Mallucci et al.
present a compelling set of observa-
tions that illustrate reversal of synaptic
and behavioral dysfunction in a mouse
prion disease model (Mallucci et al.,
2007). In many neurodegenerative
diseases, particularly those involving
pathogenic protein misfolding such
as transmissible spongioform enceph-
alopathies (TSEs) and Alzheimer’s
and Parkinson’s diseases, the window
of pathophysiological reversibility has
been difficult to define. These distinct
disease entities share some patho-
genic and biochemical features, in-
cluding conversion of a normal cellular
protein to one with an altered confor-
mation and apparent toxic action.
The exact nature of the most toxic
protein forms, the cell biologic loci of
their toxic action, and the extent to
which injured neuronal systems can
compensate are all critical issues in
the search for disease-modifying
therapies for these neurodegenerative
diseases. In each disorder, vulnerable
synapses appear to be affected early
in each disease course through mech-
anism(s) that are largely unknown. It
can be demonstrated in some animal
models of these diseases, and pre-
sumably human patients, that synaptic
dysfunction is attended by cognitive
and behavioral abnormalities (Chiti
et al., 2006). However, discordance
between histopathological featuresand behavioral deficits has been
described (Santacruz et al., 2005),
underscoring the importance of mea-
sures of clinical relevance of animal
models, including physiology and
behavior. With disease progression
the specific pathogenic proteins lead
directly and perhaps indirectly to
neuronal death, characterizing a stage
of disease likely refractory to func-
tional recovery. Unfortunately, this is
the time during which patients cur-
rently present clinically. Thus, these
potentially discrete epochs of patho-
genesis—synaptic dysfunction,
neuronal injury, and death—frame the
issue of disease reversibility and its
relationship to meaningful therapeutic
interventions.
The TSEs are pathophysiologically
characterized by conversion of a path-
ogenic protein molecule, termed PrP
scrapie (PrPSc), derived from its
normal cellular form, PrPc, through an
ill-defined misfolding process (re-
viewed in Prusiner, 2001). Importantly,
PrPSc appears capable of catalyzing
conversion of PrPc, thus rendering
the progression of disease dependent
upon expression of the substrate gene
product. Removal of the capacity to
express PrPc from neurons, the princi-
pal contributor of CNS prion protein,
enables testing of whether PrPSc
damage is reversible and at what
stage of disease.Neuron 53, FIn the current study, the investiga-
tors use the cre/loxP system to
address this issue of reversibility in
a mouse model of prion disease
(Figure 1A). Mallucci et al. (2007)
constructed bigenic mice, termed
NFH-Cre/tg37, which harbor floxed
Prnp alleles encoding the prion (PrP)
protein and a neurofilament H (NF-H)
promoter driven cre recombinase
gene. The key to their experimental
system is that the NF-H promoter
becomes active postnatally at 9–10
weeks, resulting in recombination and
permanent loss of PrP expression
within neurons thereafter. This tempo-
ral feature allowed the investigators to
establish prion infection in mice prior
to cre-mediated recombination and
then to monitor disease evolution.
When inoculated intracerebrally with
mouse-adapted scrapie prions early
in life, at 1 week postnatal, the animals
developed progressive behavioral
deficits revealed by impaired
hippocampal-dependent learning and
spontaneous burrowing and nesting.
These behavioral changes were
accompanied by electrophysiological
deficits recorded from contemporane-
ous hippocampal slices and charac-
teristic histopathological features of
spongiosis, gliosis, and PrP scrapie
containing amyloid deposits. Coinci-
dent with NF-H cre-promoted removal
of the Prnp gene and loss of PrPcebruary 1, 2007 ª2007 Elsevier Inc. 315
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PreviewsFigure 1. Postnatal Excision of Neuronal PrPC Reverses Disease Processes in Prion-Infected Mice
(A) Intracerebral (ICB) injection of PrPSc (Chandler/Rocky Mountain Laboratories mouse-passaged scrapie strain) in 1-week-old tg37 mice results in
a stereotyped pattern of disease progression, including deposition of PrPSc and a variety of histological, synaptic, and behavioral pathologies. In the
present study, cre-mediated knockout of neuronally expressed PrPC (under the control of the murine neurofilament H control elements, NFH-Cre) at
9–10 weeks of age resulted in a halting and reversal of disease processes in these bitransgenic mice.
(B) The successful treatment of the human prionoses and other neurodegenerative diseases will require a better understanding of the stages of dis-
ease pathogenesis and ‘‘windows’’ of potential therapeutic intervention. The natural history of a given disease, and the progression of its clinical
symptoms and underlying molecular/cellular changes, will necessarily dictate the success of a given treatment. For example, as was the case in
this study, interventions at subclinical and early clinical time points in disease, prior to the onset of overt neuronal death, may result in recovery of
function and a better prognosis. Alternatively, interventions at later time points where cell death is widespread may prove less efficacious at halting,
let alone reversing, disease processes. Thus, future studies will be necessary to answer the questions as to at what point and for how long particular
‘‘windows of disease reversibility’’ are open to treat this and potentially other neurodegenerative diseases.expression, scrapie-infected mice re-
covered behaviorally, physiologically,
and histopathologically (see Figures
1, 3, and 5 of Mallucci et al., 2007).
Control mice that did not carry the
cre recombinase gene and that contin-
ued to express PrPc progressively
worsened by all measures.
The importance of this work is four-
fold. First, it illustrates a clear stage
of TSE reversibility that was character-
ized by synaptic dysfunction and
correlated behavioral impairments.
Second, it underscores that PrPSc
can be cleared from the scrapie-316 Neuron 53, February 1, 2007 ª2007 Einfected nervous system and its injury
compensated by neuronal mecha-
nisms. Third, it heralds an era in thera-
peutics development for neurodegen-
erative diseases involving protein
misfolding. Finally, the findings of this
study make evident the need to better
identify patients earlier in their disease
course, when reversal and/or treat-
ment of pathophysiological processes
may be feasible.
This study, while extending our
understanding of the TSEs, raises
a number of issues. For example, the
temporal dimension of the window tolsevier Inc.achieve disease reversal is unknown
(Figure 1B). Would a greater delay in
eliminating PrPc expression, in this
context turning cre recombinase on
later within the disease course, still
reverse disease or perhaps result in
partial recovery? Next, the observa-
tions were made in very young mice in
which postnatal brain development
was still active. As such, the findings
may be less clinically relevant since
most TSEs present later in life when
synaptic plasticity appears more
limited and thus the propensity for
functional recovery less robust. Lastly,
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Previewswould hypothetical disease-modifying
strategies that could reduce but
not eliminate PrPc expression benefit
neurologically impaired patients?
Absent such information, it is important
that methods including RNAi and PrP
antibody based approaches be devel-
oped and evaluated (Donofrio et al.,
2005; Enari et al., 2001; Golding
et al., 2006; Peretz et al., 2001; Pfeifer
et al., 2006; White et al., 2003). Testing
of candidate therapeutics in animal
models could determine the optimal
timing for administration (with respect
to disease stage), the capacity to
attenuate and/or reverse features of
disease, the impact of subject age on
efficacy, and whether they are effective
singly or in combination. It is hoped
that a successful demonstration of
a preclinical therapy of a prionosis
would enable early-stage clinical trials.Picking Up the P
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Calpain-mediated cleavage of n
synaptic plasticity. In this issue
the respective roles of mGluR1a
control. Together, these papers
cleavage.
Calpain, sometimes referred to as cal-
cium-activated neutral protease, is
among the most enigmatic proteases
in the body and particularly the nervous
system (Wu and Lynch, 2006). This
family of proteases is recognized by
their requirement for calcium and
defined by specific inhibitors, but theirMoreover, the extension of this general
approach of defining a reversible
phase and enabling interventions to
the more common protein misfolding
diseases such as Alzheimer’s
and Parkinson’s should be strongly
encouraged.
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